Mελέτες που παρουσιάστηκαν:
– Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
– Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
– Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
– Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
Όλα τα Podcasts
